In a groundbreaking interdisciplinary effort, scientists have announced the discovery of a novel therapeutic agent poised to revolutionize tuberculosis treatment. Leading this initiative, Associate Professor Noriyuki Kurita of Toyohashi University of Technology, alongside Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand, harnessed cutting-edge molecular simulation technologies to design inhibitors targeting cytochrome P450 (CYP) enzymes, key players in drug metabolism that have long complicated tuberculosis pharmacotherapy.
Tuberculosis remains a global public health menace, largely due to Mycobacterium tuberculosis’ complex biology and the problematic resistance developed against conventional antibiotics. One culprit exacerbating treatment challenges is rifampicin, a frontline antitubercular drug known for inducing CYP enzymes. This induction accelerates the metabolism of co-administered medications, drastically shortening their therapeutic window and effectiveness, which often compromises multi-drug regimens essential for tuberculosis management.
To overcome these hurdles, the research team focused on developing CYP inhibitors capable of preventing the excessive metabolism mediated by these enzymes. The crux lies in the CYP heme group housing a central iron atom, whose coordination bond with inhibitors is paramount for effective suppression of CYP activity. Traditional molecular simulation methods, however, faltered in accurately capturing these metal coordination interactions and the accompanying electron transfer processes, limitations that have stymied drug design efforts for years.
Innovatively, the researchers crafted a novel molecular mechanics force field that meticulously incorporates coordination bonds and charge transfer dynamics around the heme iron center. This advancement marks a significant leap, as it allowed for faithful reproduction of the CYP-inhibitor complex structures observed experimentally. Crucially, the force field enables simulations that delve into the subtle electronic and geometric nuances governing inhibitor binding, hitherto elusive under classical computational paradigms.
To deepen their insights, the team employed the fragment molecular orbital (FMO) method, an ab initio quantum chemical approach, to dissect the electronic structure at the CYP-inhibitor interface. This analysis illuminated the specific amino acid residues within CYP responsible for stabilizing inhibitor binding via a network of hydrogen bonds, CH-π interactions, and coordination bonds. Such mechanistic clarity is foundational for rational drug design, guiding targeted modifications to enhance affinity and specificity.
Capitalizing on these revelations, the team devised a strategy to chemically modify an existing inhibitor referred to as 15b. By introducing various substituents at a key site identified via molecular simulations—highlighted by a distinctive red circle in their structural model—they systematically explored derivative compounds with potentially superior binding profiles. This iterative approach yielded eleven promising candidates exhibiting balanced drug-like properties and minimal predicted toxicity, a vital consideration often overlooked in early-stage in silico screening.
Subsequent simulations leveraging state-of-the-art supercomputing resources rigorously evaluated the interaction energies and binding modes of these candidates with CYP. Remarkably, two compounds surpassed existing inhibitors in binding strength, underscoring their potential as next-generation CYP inhibitors capable of mitigating excessive enzymatic degradation of co-administered drugs during tuberculosis treatment.
Behind the scenes, this endeavor was propelled by the dedication of graduate students Y. Nagura and N. Chimura, whose efforts in refining the force field and conducting comprehensive simulations were pivotal. Their collaboration with the Thai research group not only underscored the importance of cross-cultural scientific exchange but also exemplified how direct dialogue accelerates problem-solving and innovation, paving the way for breakthroughs in drug discovery.
Looking ahead, the research team plans to expand the application of their advanced simulation framework to other enzyme targets implicated in human diseases. Synthesis of the lead candidates will be undertaken in Thai laboratories, complemented by cell-based assays to empirically validate inhibitory efficacy and cytotoxicity profiles. This tightly integrated computational-experimental pipeline promises to streamline drug development, reducing timelines and costs associated with traditional approaches.
Moreover, sustained bilateral cooperation between Toyohashi University of Technology and Ubon Ratchathani University—now spanning over a decade—continues to foster an environment conducive to scientific excellence and innovation. The planned exchange of researchers and students ensures knowledge transfer and capacity building, further amplifying the impact of this research endeavor on global health challenges.
This initiative was supported by the Japan Student Services Organization’s International Internship Program and facilitated via an established student and research exchange program between the Japanese and Thai institutions. Additionally, computational analyses were conducted on the Fugaku supercomputer at RIKEN, underscoring the critical role of high-performance computing in addressing complex biochemical questions.
These advancements reflect a paradigm shift in drug discovery, where precise molecular modeling of metalloproteins integrates seamlessly with fragment-based quantum calculations to unravel intricate binding phenomena. As tuberculosis continues to claim millions of lives annually, the emergence of such sophisticated tools and collaborative research efforts inject fresh hope into developing durable, resistance-resilient therapeutic options.
Subject of Research: Not applicable
Article Title: Proposal of novel CYP3A4 inhibitors: Molecular simulations based on molecular mechanics and ab initio fragment molecular orbital methods
News Publication Date: 12-May-2026
Web References: http://dx.doi.org/10.1016/j.insi.2026.100373
References:
[1] Y. Nagura et al., Modification of MM force fields around heme-Fe in the CYP-ligand complex and ab initio FMO calculations for the complex, J. Mol. Graph. Model., 133, 108875 (2024).
[2] N. Chimura et al., Proposal of novel CYP3A4 inhibitors: Molecular simulations based on molecular mechanics and ab initio fragment molecular orbital methods, In Silico Research in Biomedicine, 2, 100373 (2026).
Image Credits: COPYRIGHT(C) TOYOHASHI UNIVERSITY OF TECHNOLOGY. ALL RIGHTS RESERVED.
Keywords
Tuberculosis, Cytochrome P450, CYP3A4, molecular simulation, fragment molecular orbital method, heme iron, drug metabolism, drug resistance, enzyme inhibition, molecular mechanics force field, computational drug design, supercomputing
Tags: CYP enzyme metabolismcytochrome P450 inhibitorselectron transfer in enzyme inhibitionhigh-precision molecular simulationsinterdisciplinary pharmaceutical researchmetal coordination in drug designmulti-drug tuberculosis therapyMycobacterium tuberculosis resistancenovel tuberculosis therapeuticsrifampicin drug interactionstuberculosis drug developmenttuberculosis treatment innovation
